End-stage Liver Disease in Children

Robert H. Squires1

  • 1Liver Transplantation Program, Children's Medical Center of Dallas, 1935 Motor Street, Dallas, TX 75235, USA. rsquires@childmed.dallas.tx.us

Insights

Managing pediatric end-stage liver disease requires addressing nutritional issues, ascites, pruritus, and encephalopathy. Treatment plans must adapt to the child

Area of Science:

  • Pediatric Gastroenterology and Hepatology
  • Critical Care Medicine
  • Transplant Surgery

Background:

  • End-stage liver disease (ESLD) in children presents complex challenges requiring multidisciplinary management.
  • Caregiver involvement is crucial for implementing treatment plans tailored to a child's developmental stage.

Purpose of the Study:

  • To outline comprehensive management strategies for pediatric ESLD.
  • To detail approaches for nutritional deficiencies, ascites, pruritus, encephalopathy, and portal hypertension.

Main Methods:

  • Routine monitoring and supplementation of fat-soluble vitamins (A, D, E, K) and micronutrients.
  • Pharmacological interventions including spironolactone, diuretics, ursodeoxycholic acid, rifampin, lactulose, and protein restriction.
  • Procedural interventions such as paracentesis, endoscopic variceal banding/sclerotherapy, surgical shunting, and orthotopic liver transplantation.

Main Results:

  • Nutritional support and vitamin/micronutrient supplementation are vital for growth.
  • Ascites and pruritus often respond to medical management, with procedural interventions reserved for refractory cases.
  • Hepatic encephalopathy management involves monitoring serum ammonia and implementing dietary changes and lactulose.

Conclusions:

  • Effective management of pediatric ESLD necessitates a coordinated approach addressing multiple complications.
  • Liver transplantation remains a definitive option for children with end-stage liver disease unresponsive to other treatments.

Related Concept Videos

Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...